- Home
- LVTX vs CALC Comparison
LVTX vs CALC Comparison
Compare LVTX & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LVTX
- CALC
- Stock Information
- Founded
- LVTX 2016
- CALC 2011
- Country
- LVTX Netherlands
- CALC United States
- Employees
- LVTX N/A
- CALC N/A
- Industry
- LVTX Biotechnology: Pharmaceutical Preparations
- CALC Biotechnology: Pharmaceutical Preparations
- Sector
- LVTX Health Care
- CALC Health Care
- Exchange
- LVTX Nasdaq
- CALC Nasdaq
- Market Cap
- LVTX 33.9M
- CALC 32.4M
- IPO Year
- LVTX 2021
- CALC N/A
- Fundamental
- Price
- LVTX $1.43
- CALC $3.80
- Analyst Decision
- LVTX Hold
- CALC Strong Buy
- Analyst Count
- LVTX 3
- CALC 2
- Target Price
- LVTX $1.75
- CALC $14.50
- AVG Volume (30 Days)
- LVTX 30.6K
- CALC 133.2K
- Earning Date
- LVTX 08-19-2025
- CALC 08-11-2025
- Dividend Yield
- LVTX N/A
- CALC N/A
- EPS Growth
- LVTX N/A
- CALC N/A
- EPS
- LVTX N/A
- CALC N/A
- Revenue
- LVTX $4,990,000.00
- CALC N/A
- Revenue This Year
- LVTX N/A
- CALC N/A
- Revenue Next Year
- LVTX N/A
- CALC N/A
- P/E Ratio
- LVTX N/A
- CALC N/A
- Revenue Growth
- LVTX N/A
- CALC N/A
- 52 Week Low
- LVTX $0.85
- CALC $1.42
- 52 Week High
- LVTX $2.21
- CALC $5.97
- Technical
- Relative Strength Index (RSI)
- LVTX 58.31
- CALC 73.90
- Support Level
- LVTX $1.40
- CALC $3.37
- Resistance Level
- LVTX $1.67
- CALC $4.26
- Average True Range (ATR)
- LVTX 0.10
- CALC 0.41
- MACD
- LVTX 0.00
- CALC 0.21
- Stochastic Oscillator
- LVTX 33.33
- CALC 82.80
About LVTX LAVA Therapeutics N.V.
LAVA Therapeutics NV isa clinical stage immuno-oncology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer. Company's pipeline include's products such as LAVA-1266, LAVA-1427, LAVA-1433, LAVA-1207, PF08046052, JNJ89853413.
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.